Transmembrane domain targeting peptide antagonizing ErbB2/Neu inhibits breast tumor growth and metastasis

Cell Reports

Volumn 8, Issue 6, 2014, Pages 1714-1721

  Arpel, Alexia ^a   Sawma, Paul ^b   Spenlé, Caroline ^a   Fritz, Justine ^a   Meyer, Lionel ^a   Garnier, Norbert ^c   Velázquez Quesada, Inés ^a   Hussenet, Thomas ^a   Aci Sèche, Samia ^c   Baumlin, Nadège ^a   Genest, Monique ^c   Brasse, David ^a   Hubert, Pierre ^b   Crémel, Gérard ^a   Orend, Gertraud ^a   Laquerrière, Patrice ^a   Bagnard, Dominique ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c UNIVERSITÉ D'ORLÉANS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PEPTIDE; PROTEIN KINASE B; TRANSMEMBRANE DOMAIN TARGETING PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIMARY TUMOR; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BREAST NEOPLASMS; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; LUNG TUMOR; MCF 7 CELL LINE; METABOLISM; MOLECULAR GENETICS; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; RADIOGRAPHY; SECONDARY; TRANSGENIC MOUSE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MCF-7 CELLS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDES; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84907397425     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.07.044     Document Type: Article

References (25)

1. Arkhipov A., Shan Y., Das R., Endres N.F., Eastwood M.P., Wemmer D.E., Kuriyan J., Shaw D.E. Architecture and membrane interactions of the EGF receptor. Cell 2013, 152:557-569.
2. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012, 9:16-32.
3. Bagossi P., Horváth G., Vereb G., Szöllösi J., Tözsér J. Molecular modeling of nearly full-length ErbB2 receptor. Biophys. J. 2005, 88:1354-1363.
4. Bennasroune A., Fickova M., Gardin A., Dirrig-Grosch S., Aunis D., Crémel G., Hubert P. Transmembrane peptides as inhibitors of ErbB receptor signaling. Mol. Biol. Cell 2004, 15:3464-3474.
5. Bocharov E.V., Volynsky P.E., Pavlov K.V., Efremov R.G., Arseniev A.S. Structure elucidation of dimeric transmembrane domains of bitopic proteins. Cell Adhes. Migr. 2010, 4:284-298.
6. Bombonati A., Sgroi D.C. The molecular pathology of breast cancer progression. J.Pathol. 2011, 223:307-317.
7. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2:563-572.
8. Charafe-Jauffret E., Tarpin C., Bardou V.-J., Bertucci F., Ginestier C., Braud A.-C., Puig B., Geneix J., Hassoun J., Birnbaum D., et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J.Pathol. 2004, 202:265-273.
9. Cymer F., Schneider D. Transmembrane helix-helix interactions involved in ErbB receptor signaling. Cell Adhes. Migr. 2010, 4:299-312.
10. Eccles S.A. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int. J. Dev. Biol. 2011, 55:685-696.
11. Endres N.F., Das R., Smith A.W., Arkhipov A., Kovacs E., Huang Y., Pelton J.G., Shan Y., Shaw D.E., Wemmer D.E., et al. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 2013, 152:543-556.
12. Freudenberg J.A., Wang Q., Katsumata M., Drebin J., Nagatomo I., Greene M.I. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp. Mol. Pathol. 2009, 87:1-11.
13. Grunt T.W., Mariani G.L. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling. Curr. Cancer Drug Targets 2013, 13:188-204.
14. Karimova G., Ullmann A., Ladant D. Protein-protein interaction between Bacillus stearothermophilus tyrosyl-tRNA synthetase subdomains revealed by a bacterial two-hybrid system. J.Mol. Microbiol. Biotechnol. 2001, 3:73-82.
15. Kim D., Chung J. Akt: versatile mediator of cell survival and beyond. J.Biochem. Mol. Biol. 2002, 35:106-115.
16. Lofts F.J., Hurst H.C., Sternberg M.J., Gullick W.J. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor invitro and invivo. Oncogene 1993, 8:2813-2820.
17. Muller W.J., Sinn E., Pattengale P.K., Wallace R., Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54:105-115.
18. Nasarre C., Roth M., Jacob L., Roth L., Koncina E., Thien A., Labourdette G., Poulet P., Hubert P., Crémel G., et al. Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth invivo. Oncogene 2010, 29:2381-2392.
19. Popot J.-L., Althoff T., Bagnard D., Banères J.-L., Bazzacco P., Billon-Denis E., Catoire L.J., Champeil P., Charvolin D., Cocco M.J., et al. Amphipols from A to Z. Annu Rev Biophys 2011, 40:379-408.
20. Roberts P.J., Usary J.E., Darr D.B., Dillon P.M., Pfefferle A.D., Whittle M.C., Duncan J.S., Johnson S.M., Combest A.J., Jin J., et al. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin. Cancer Res. 2012, 18:5290-5303.
21. Ross J.S., Fletcher J.A. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin. Cancer Biol. 1999, 9:125-138.
22. Siegel P.M., Shu W., Cardiff R.D., Muller W.J., Massagué J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl. Acad. Sci. USA 2003, 100:8430-8435.
23. Weiner D.B., Kokai Y., Wada T., Cohen J.A., Williams W.V., Greene M.I. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Oncogene 1989, 4:1175-1183.
24. Yamaguchi H., Chang S.-S., Hsu J.L., Hung M.-C. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene 2014, 33:1073-1081.
25. Yang Y.-A., Dukhanina O., Tang B., Mamura M., Letterio J.J., MacGregor J., Patel S.C., Khozin S., Liu Z.-Y., Green J., et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J.Clin. Invest. 2002, 109:1607-1615.